Incyte Corp. Third Quarter 2026 Earnings Call - MORPHOSYS AG

Financial Performance:

• Total revenue for Q3 2026 was $1.56 billion, up 14% year-over-year; total net sales reached $1.32 billion, also up 14%.
• Jackify franchise net sales were $827 million (+4% YoY), with underlying demand up 12%; Jackify XR sales were $15 million, capturing ~3% market share.
• Non-Jackify core business sales grew 30% YoY to $490 million, driven by Opsalora, Nick Timbo, Zionist, and Monjuvi.
• Opsalora net sales were $255 million (+36% YoY); U.S. sales rose 45% (25% pro forma) and international sales rose 5% (20% underlying).
• Hematology and Oncology franchise sales were $235 million (+38% YoY), led by Nick Timbo ($67M, +47%), Zionist ($58M, +157%), and Monjuvi ($55M, +30%).
• GAAP operating expenses were $2.27 billion due to $1.23 billion in one-time IPR&D expense from the Vega Therapeutics acquisition; excluding this, operating expenses grew 12%.
• GAAP R&D was $1.79 billion (+254% YoY); excluding acquisition, it rose 11%. GAAP SG&A was $364 million (+11% YoY).
• Cash and cash equivalents at quarter-end were $3.9 billion.

Guidance and Future Outlook:

• Maintained full-year Jackify revenue guidance of $3.22 billion to $3.27 billion, having absorbed the ~1% CMS generic model impact.
• Raised full-year Opsalora net sales guidance to $1.10 billion to $1.12 billion.
• Raised full-year Hematology and Oncology guidance to $890 million to $910 million.
• Increased total net sales guidance to $5.21 billion to $5.30 billion.
• Maintained full-year operating expense guidance, expecting R&D and SG&A to be mid-range of the updated forecast.
• Long-term goal: Core non-Jackify business to grow to $3–4 billion by 2030; target to retain 10–30% of the Jackify business by 2029 via XR uptake.
• Opsalora XR target: Achieve ~$50 million in net sales by year-end 2026.

Business Segments and Product Lines:

• Dermatology: Opsalora launched in EU for moderate Atopic Dermatitis (AD); Povercitinib (povocitinib) received positive CHMP opinion for moderate-to-severe Hidradenitis Suppurativa (HS) in EU, with U.S. NDA review ongoing for Q1 2027 approval.
• Hematology: Monjuvi approved in Europe and Japan for Follicular Lymphoma; Tapacitumab (NDA) review ongoing for frontline DLBCL with approval expected Q1 2027.
• Oncology: 734 (G12D inhibitor) showing 58–81% objective response rates in PDAC and 36% in CRC; Phase III studies planned for adjuvant PDAC and frontline CRC. 890 (TGF-beta/PD-1 bispecific) showing 71% response in MSS-CRC; Phase III NEXERA-303 underway.
• Pipeline Expansion: Acquired Vega Therapeutics for Latarcibar (Protein S modulator for von Willebrand disease); Phase III ongoing with top-line data expected early 2029.
• Asset Discontinuation: Deprioritized CDK2 inhibitor (667) in platinum-resistant ovarian cancer; focusing development on first-line maintenance for Cyclin E1 overexpressing ovarian cancer.

Market and Competitive Landscape:

• Opsalora leads in AD/Vitiligo with 20,000 prescribers and >250,000 patients; new patient starts up 26%, outpacing market growth.
• Zionist is the leading first-line and only FDA-approved first-line treatment for SCA.
• Competitors in OPN (MPN) space face challenges regarding long-term durability; 989 targets mutation-specific pathology.
• Strong formulary coverage for Jackify XR expected to exceed 80% by year-end.
• International adoption of Opsalora for AD expected to expand across Germany and Europe in mid-2027.

Risks and Challenges:

• Regulatory Risk: Reliance on FDA/EMA approvals for Monjuvi, Povocitinib, and various pipeline assets (989, 734, 890); future labeling scenarios for Povocitinib remain uncertain.
• Clinical Execution: Enrollment risks in late-stage trials (e.g., 989 frontline MF, 734 PDAC/CRC) due to competition and changing standard of care (e.g., use of Xolair/Daxxif).
• Pricing/Reimbursement: CMS Generic Model impact on Jackify pricing; need to maintain formulary access amidst potential price maintenance strategies.
• Pipeline Attrition: Probability of success varies; assets like TGF-beta/PD-1 carry higher biological risk, while others (989, 734, 734, 890) are higher risk/higher return.
• Commercialization: Execution risk in managing high-quality Phase 3 programs and achieving regulatory milestones on time.

Management Commentary and Tone:

• Tone is confident and strategic, emphasizing a transition from a single-product company to a diversified pipeline leader.
• Management highlighted "execution risk" as the primary remaining hurdle, citing control over enrollment and regulatory milestones.
• Repeated emphasis on data-driven decision-making, including the deprioritization of CDK2 in ovarian cancer to focus on higher-value settings.
• Expressions of strong confidence in the late-stage pipeline's ability to drive growth post-2029 and support the company through the Jackify patent cliff.

Analyst Questions and Answers:

• 989 (MCALR) Frontline MF: Data presentation delayed to ASH 2027 to ensure maturity; study design (monotherapy vs. combo with ruxolitinib) pending FDA Type C meeting discussions on composite endpoints (hematopoiesis, spleen, symptoms).
• 989 Second-Line MF: Primary endpoint focused on Type 1 mutations (70% of population); no minimum prior JAK inhibitor duration defined, allowing physician discretion.
• Opsalora Growth: Q3 growth driven by underlying demand (24% increase) and new patient starts (26% increase) rather than price hikes; price expected to remain stable in 2027+.
• Povocitinib (Povercitinib) HS Label: FDA discussions ongoing; aiming for broad label covering both pre-biologic and post-biologic patients; potential for $50–100M incremental sales from mild/moderate HS indication.
• 734 (G12D) Enrollment: Phase III enrollment on track in US; monitoring post-progression use of adavosertib (Doxrubicin?) to prevent imbalance in PFS2 analysis.
• Next-Gen Cal-AR: Expected to enter clinic early 2027; preclinical data shows 70x potency against non-Type 1 mutations and longer half-life (monthly dosing potential).
• Vega Acquisition: Latarcibar pivotally evaluated for von Willebrand disease; Phase III top-line expected 2029.
• Pan-RAS/G12V: No current plans to license G12V but open to expansion; continuing to evaluate pan-RAS combinations for G12D.

Other Key Points:

• Vega Acquisition Details: Total cash consideration approx. $1.27 billion, including $1.23 billion IPR&D expense; asset Latarcibar is a novel protein S modulator.
• Pipeline Milestones: Over 10 pivotal trials underway; moved from early clinical to registrational development across multiple assets in one year.
• Future Clinical Updates: Key data expected at ASH (989), ESMO (734/890), and Q1 2027 (Tapacitumab, Povocitinib axotilimab GVHD data).
• Strategic Shift: Clear transition focus on scaling the core business (non-Jackify) to $3-4B by 2030 while funding a late-stage pipeline to replace Jackify by 2029.